Market revenue in 2020 | USD 364.9 million |
Market revenue in 2028 | USD 812.7 million |
Growth rate | 10.5% (CAGR from 2020 to 2028) |
Largest segment | Laboratory technologies |
Fastest growing segment | Online Technologies |
Historical data | 2020 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Laboratory Technologies, Online Technologies |
Key market players worldwide | Thermo Fisher Scientific Inc, Pfizer Inc, Sartorius AG, Stemcell Holdings Inc Ordinary Shares, Illumina Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Merck KGaA, Qiagen NV, Shimadzu Corp, Eurofins Scientific SE, Charles River Laboratories International Inc, Takara Bio Inc, Olympus Corp, Avantor Inc, Aurora Innovation Inc Class A, Standard BioTools Inc, Celerion, Cole-Parmer, Hartford Schroders International Stk I, Revvity Inc, Fluidigm Corporation, Polyplus-transfection, Hamilton Lane Inc Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to covid-19 vaccine development tools market will help companies and investors design strategic landscapes.
Laboratory technologies was the largest segment with a revenue share of 95.2% in 2020. Horizon Databook has segmented the Italy covid-19 vaccine development tools market based on laboratory technologies, online technologies covering the revenue growth of each sub-segment from 2020 to 2028.
Italy is an emerging healthcare market and COVID-19 created a significant opportunity for the companies. The market in the region was supported by local biotechnology companies and initiatives undertaken by them to produce in-house COVID-19 vaccines.
For instance, in February 2021, Takis, an Italian-based biotech company, received approval from the national drug regulator for its COVID-19 vaccine. The company is anticipated to initiate clinical trials in March 2021.
COVID-eVax is Italy’s second COVID-19 vaccine candidate, which is based on a DNA fragment injected into the muscles to increase production of the virus' spike protein and stimulate an immune reaction. The company employed electroporation technology along with a mini electric jolt, as DNA is a larger molecule than RNA.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy covid-19 vaccine development tools market , including forecasts for subscribers. This country databook contains high-level insights into Italy covid-19 vaccine development tools market from 2020 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account